SWKH - SWK Holdings Corporation Announces 2019 First Quarter Financial Results

• Total revenues of approximately $9.4 million for the first quarter of 2019 compared to $6.8 million for the first quarter of 2018.
  
  
• Net income of $6.6 million, or $0.51 per share, and non-GAAP Adjusted net income of $7.4 million, or $0.57 per share for the first quarter of 2019.
  
  
• Closed two financings deploying $11.2 million. Post quarter close deployed $5.0 million with potential additional add-on funding of $7.5 million to existing portfolio companies.
  
  
• Book value of $16.98 per share as of March 31, 2019 vs. $16.47 per share as of December 31, 2018.

DALLAS, May 15, 2019 (GLOBE NEWSWIRE) -- SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its first quarter 2019 financial results.

First Quarter 2019 Highlights:

• Reported total revenues of approximately $9.4 million for the quarter, compared to $6.8 million for the first quarter of 2018.
  
  
• Reported adjusted net income of approximately $7.4 million, or $0.57 per diluted share, for the quarter, as compared to $4.4 million, or $0.34 per diluted share, for the first quarter of 2018.
  
  
• Total income producing assets (defined as finance receivables and corporate debt securities) were approximately $154.9 million as of March 31, 2019, compared to $167.1 million as of December 31, 2018.
  
  
• Repurchased 77,300 shares during the quarter at an average cost of $9.63 per share. Since November 2018 SWK has repurchased 222,366 shares at an average cost of $9.68 per share. 

“We are pleased with the strong first quarter results highlighted by the closing of two new transactions, as well as, advancing additional capital to current partners subsequent to quarter close.” stated Winston Black, Chief Executive Officer of SWK. “We are also pleased to support the pending acquisition of Solsys Medical LLC by Misonix Inc. via an upsized facility. We anticipate closing additional deals during the balance of the year and remain highly focused on increasing shareholder value."

Note:

• All references to growth rate percentages and shares compare the results of the period to those of the prior year comparable period.
  
  
• The Company reports its financial results in accordance with Generally Accepted Accounting Principles in the U.S. (“GAAP”).  However, management believes that certain non-GAAP financial measures provide users with additional meaningful financial information that should be considered when assessing the Company’s ongoing performance. Non-GAAP financial measures should be viewed in addition to, and not as an alternative for, the Company’s reported results prepared in accordance with GAAP. The Company’s non-GAAP financial information does not represent a comprehensive basis of accounting. Management also uses these non-GAAP financial measures in making financial, operating and planning decisions and in evaluating the Company's performance.
  
  
• Non-GAAP Adjusted net income and its components and Non-GAAP Adjusted basic and diluted EPS are not, and should not be viewed as, substitutes for GAAP net income and its components and basic and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, we stress that these are Non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, Non-GAAP Adjusted net income and its components (unlike GAAP net income and its components) may not be comparable to the calculation of similar measures of other companies.

Portfolio Overview

As of March 31, 2019, the Company's total income producing assets were approximately $154.9 million as compared to $167.1 million as of December 31, 2018.

During the quarter, the Company deployed $10.0 million via a new term loan to Cheetah Medical, Inc. and $1.2 million through the participation in a term loan to Aimmune Therapeutics, Inc., for a total of $11.2 million.  These deployments were offset by a $20.0 million repayment of the EyePoint Pharmaceuticals term loan.

Post quarter close, SWK supported BIOLASE, Inc.’s capital needs through an additional $2.5 million of funding. The Company also helped facilitate the merger of Solsys Medical, LLC (“Solsys”) and Misonix, Inc. (“Misonix”) by advancing Solsys an incremental $2.5 million, with an additional $2.5 million if certain conditions are achieved; SWK also committed to advance Misonix an additional $5.0 million post consummation of the merger, if closed.   

As of May 15, 2019, the Company and its partners have executed transactions with 34 different parties under its specialty finance strategy, funding an aggregate $499 million since 2012 in various financial products across the life science sector.  At the end of the third quarter, the weighted average projected effective yield of the finance receivables portfolio was 15.0%.  The projected effective yield is the rate at which income is expected to be recognized pursuant to the Company’s revenue recognition policies, if all payments are received pursuant to the terms of the finance receivables.

Total portfolio investment activity as of and for the three months ended March 31, 2019 was as follows (in thousands):

Update on Share Repurchase Program

On December 21, 2018, SWK implemented the $3.5 million share repurchase program, or approximately 312,491 common shares,  that its Board of Directors authorized to be executed in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Securities Exchange Act. The purchase period is December 21, 2018 through May 31, 2019. 

As of May 14, 2019, the Company has repurchased 222,366 shares of its outstanding shares of common stock. Of the total 222,366 shares, 137,800 were repurchased under the share repurchase program at a total cost of $1.3 million, or $9.58 per share. As of March 31, 2019, the maximum number of shares that may yet be purchased under the plan is 174,691 shares.

Results of Operations

Revenues

We generated revenues of $9.4 million and $6.8 million for the three months ended March 31, 2019 and 2018, respectively, which consisted of interest and fees earned on our finance receivables. The increase in revenue is primarily due to a $2.5 million increase in interest and fees earned on new and existing finance receivables and $3.4 million in exit and prepayment fees from a loan payoff. The increase in revenue was offset by a $2.6 million decrease in interest and fees earned on finance receivables that were paid off or paid down in 2018.

Provision for Credit Losses and Impairment Expense

During the three months ended March 31, 2019, we recognized credit loss provision expense of $0.6 million related to the Besivance® royalty, which was due to increases in sales chargebacks and various rebates (gross sales to net sales deductions) and lower sales volumes. We recognized an allowance for credit losses on a royalty of $1.2 million during the three months ended March 31, 2018. Please refer to Part I. Financial Information, Item 1. Financial Statements, Note 3 of the Notes to the Unaudited Condensed Consolidated Financial Statements for further information on the provision for credit losses recognized during the three months ended March 31, 2019.

General and Administrative

General and administrative expenses consist primarily of compensation, stock-based compensation and related costs for management, staff, Board of Directors, legal and audit expenses, and corporate governance. General and administrative expenses increased to $1.3 million for the three months ended March 31, 2019 from $1.2 million for the three months ended March 31, 2018, which was primarily due to an increase in the performance-based bonus accrual.

Other Income (Expense), Net
Other income for the three months ended March 31, 2019 reflected a net fair market value gain of $0.3 million on our warrant derivatives. Other income for the three months ended March 31, 2018, reflected a net fair market value gain of $0.3 million on our warrant derivatives and a net fair market value loss of $0.1 million on our equity securities.

Income Tax (Benefit) Expense
We recognized deferred income tax expense of $1.1 million and $1.0 million during the three months ended March 31, 2019 and 2018, respectively. The increase in deferred income tax expense was primarily due to an increase in net income.

Liquidity and Capital Resources

As of March 31, 2019, we had $39.2 million in cash and cash equivalents, compared to $20.2 million in cash and cash equivalents as of December 31, 2018. The primary driver of the net increase in our cash balance was $23.3 million related to the payoff of one finance receivable, offset by new and add-on investment funding of $11.2 million.

As of March 31, 2019, we had $5.8 million of unfunded commitments outstanding.  Subsequent to quarter close a $2.0 million unfunded commitment to Veru was eliminated while a $2.5 million unfunded commitment to Solsys Medical was signed.   

Adjusted Net Income

Net income in accordance with GAAP for the three month period ended March 31, 2019, was $6.6 million, or $0.51 per diluted share. The table below eliminates provisions for income taxes, non-cash mark-to-market changes on warrant assets and SWK's warrant liability.

The following tables provide a reconciliation of SWK’s reported (GAAP) consolidated net income to SWK’s adjusted net income attributable to SWK Holdings Corporation Stockholders (Non-GAAP) for the three ended March 31, 2019 and March 31, 2018:

In the presentation above, management has deducted the following non-cash items: (i) fair-market value of warrants as mark to market changes are non-cash, and (ii) income taxes as the Company has substantial net operating losses to offset against future income.

About SWK Holdings Corporation

SWK Holdings Corporation is a specialized finance company with a focus on the global healthcare sector.  SWK partners with ethical product marketers and royalty holders to provide flexible financing solutions at an attractive cost of capital to create long-term value for both SWK’s business partners and its investors.  SWK believes its financing structures achieve an optimal partnership for companies, institutions and inventors seeking capital for expansion or capital and estate planning by allowing its partners to monetize future cash flow with minimal dilution to their equity stakes. Additional information on the life science finance market is available on the Company’s website at www.swkhold.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,” “look forward,” “intend,” “guidance,” “future” or similar expressions are forward-looking statements. Because these statements reflect SWK’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption “Risk Factors” in SWK’s Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect the Company’s future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Company’s actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made.  We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

CONTACT: SWK Investor Relations at (972) 687-7250 or investor.relations@swkhold.com.